Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 1 | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | — | 1 |
Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | — | — | — | 1 |
Drug common name | Dulanermin |
INN | dulanermin |
Description | Dulanermin is a protein pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Protein |
Drug class | growth factors: tumor necrosis factors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2107846 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | L65E7T81M5 (ChemIDplus, GSRS) |